Latest news with #Reddy'sLaboratories
Time of India
2 days ago
- Business
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda
Global biotech major Alvotech and Hyderabad-based Dr Reddy's Laboratories (DRL) have entered into a collaboration to co-develop, manufacture, and commercialise a biosimilar version of Merck's blockbuster cancer drug Keytruda (pembrolizumab), which recorded global sales of $29.5 billion in 2024. Shares of DRL rose 3 per cent on Thursday on the BSE following the announcement. Under the agreement, both parties will jointly manage development and manufacturing responsibilities, while sharing associated costs. Each company will also hold global commercialisation rights, subject to certain exceptions. Keytruda, developed by Merck & Co., is used to treat a wide range of cancers, including lung, melanoma, and head and neck cancers. With patents for Keytruda expected to expire in major markets over the next few years, competition among biosimilar developers is intensifying. The partnership is a strategic boost to Dr Reddy's oncology portfolio—a key therapeutic area for the company—and significantly expands Iceland-based Alvotech's biosimilar pipeline. The tie-up comes amid growing global demand for cost-effective biologic alternatives in cancer care, especially in immuno-oncology, where Keytruda remains a dominant therapy. 'We are happy to collaborate with Alvotech for the pembrolizumab biosimilar,' said Erez Israeli, CEO of Dr Reddy's. 'Oncology has been a top focus therapy area for us, and this collaboration further enhances our capabilities.' Alvotech Chairman and CEO Róbert Wessman said the partnership would accelerate development while broadening global access to critical biologics. 'This agreement demonstrates our ability to leverage our R&D and manufacturing platform to pursue growing global markets,' he said. Alvotech, listed on Nasdaq, is focused solely on biosimilars and already has approvals for adalimumab and ustekinumab biosimilars. Its pipeline includes candidates for autoimmune, respiratory, and oncologic indications. Dr Reddy's, which has commercialised six biosimilars in India and over 30 countries, has been scaling up global biologics operations. It launched its first biosimilar in the UK—Versavo (bevacizumab)—in 2024, and pegfilgrastim in the US and Europe through partners. With this collaboration, both companies aim to play a larger role in shaping the next phase of affordable cancer care globally.
The Hindu
2 days ago
- Business
- The Hindu
Dr. Reddy's, Alvotech to co-develop, market biosimilar of Merck's cancer drug Keytruda
Pharma major Dr. Reddy's Laboratories and Nasdaq-listed global biotech firm Alvotech will co-develop, manufacture and commercialise a biosimilar candidate to Merck's cancer drug Keytruda (pembrolizumab) for global markets. They will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs as well as the responsibilities. 'Subject to certain exceptions, each party will have the right to commercialise the product globally,' Dr. Reddy's and Alvotech said on Thursday (June 5, 2025) in a joint statement announcing the signing of a licence agreement. The collaboration will combine their proven capabilities in biosimilars thus speeding up the development process and extending global reach for the biosimilar candidate. A registered trademark of Merck Sharp & Dohme Corp, Keytruda is indicated for the treatment of numerous cancer types. In 2024, the worldwide sales of Keytruda were $29.5 billion. Oncology top focus therapy 'Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' Dr. Reddy's CEO Erez Israeli said. Alvotech chairman and CEO Robert Wessman said 'we are pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets.'
New Indian Express
2 days ago
- Business
- New Indian Express
Dr Reddy's–Alvotech deal: Why investors are bullish
CHENNAI: Shares of Dr Reddy's Laboratories surged over 3% in early trade on Thursday after the Indian drug maker announced a global licensing agreement with Alvotech, an Iceland-based biopharmaceutical company. Under this agreement, the two firms will codevelop, manufacture, and commercialise a biosimilar candidate to Keytruda (called as pembrolizumab by the biological name) — a blockbuster cancer immunotherapy drug originally developed by the US pharma major Merck & Co., also known as MSD Pharmaceuticals outside US. Keytruda, prescribed for the treatment of various cancers including melanoma, non-small cell lung cancer, and head and neck cancers, in adults and children, is one of the most sold drugs of Merck from its original research. According to Merck's 2024 sales data, this drug alone contributed over $29.5 billion in revenue for the company, which also makes it one of the world's top-selling drugs. This drug is in demand as it is used in advanced, metastatic, or recurrent cancers that are not responding to other treatments or cannot be removed by surgery. Keytruda can also be used to prevent cancer recurrence after surgery. A biosimilar is a generic equivalent of a biological drug. In this case, the biosimilar -- pembrolizumab-- can enter the market once Merck's patent is expired. There are several drug firms work on this bio-molecule currently worldwide, and Alvotech is one of the frontrunners. The licensing deal signed between Dr Reddy's and Alvotech marks a strategic expansion of the former's biosimilars pipeline, aligning with the company's ambition to build a strong presence in the global oncology space.
Time of India
2 days ago
- Business
- Time of India
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment
Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets, Dr Reddy's Laboratories said in a statement. Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Con la ayuda de la IA y los CFDs, una inversión puede convertirse en tu ingreso adicional. Trade AI Undo In 2024, worldwide sales of Keytruda were USD 29.5 billion. The collaboration combines Dr Reddy's and Alvotech's proven capabilities in biosimilars thereby speeding up the development process and extending the global reach for this biosimilar candidate, the company noted. Live Events Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, it stated. Subject to certain exceptions, each party will have the right to commercialize the product globally, it added. "Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ," Dr Reddy's CEO Erez Israeli said. Alvotech chairman and CEO Robert Wessman said the agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of its pipeline by pursuing growing global markets. "It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide," he added. Dr Reddy's shares were trading 3.49 per cent up at Rs 1,295.80 apiece on BSE .
